MOTS-c vs Sermorelin
Side-by-Side Comparison
| Attribute | Mots C | Sermorelin |
|---|---|---|
| Category | Metabolic / Mitochondrial | Growth Hormone Secretagogue |
| Mechanism | MOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into energy-efficient mode: enhancing glucose uptake, fatty-acid... | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. |
| Evidence Rating | D — Preclinical | C — Phase I–II Clinical Trials |
| Clinical Status | Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only) | Previously FDA-approved (Geref, discontinued); now used off-label via compounding |
| Safety Profile | No adverse effects reported in preclinical animal studies; Human tolerability is completely unknown for native MOTS-c (no completed human trials) | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 5–10 mg SC per injection | 100–300 mcg/day SC |
| Frequency | Once daily or 3–5x weekly | Once daily (typically before bed) |
| Molecular Weight | ~2174.6 g/mol | ~3357.9 g/mol |
| Half-Life | Several hours; tissue effects may persist longer | ~10–20 minutes |
Overview
MOTS-c and Sermorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
MOTS-c — Mechanism & Evidence
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.
Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for the diagnosis and treatment of growth hormone deficiency in children, though the product was voluntarily discontinued for commercial reasons — the FDA confirmed in 2013 it was not withdrawn for safety reasons. It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
MOTS-c is also researched for: Metabolic Health.
Sermorelin is also researched for: Body Composition, Sleep.
Safety Considerations
MOTS-c: No adverse effects reported in preclinical animal studies Human tolerability is completely unknown for native MOTS-c (no completed human trials) Modified analog CB4211 showed good tolerability in Phase 1
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
Related Products
Sermorelin 5mg
5mg
MOTS-C 20mg
20mg
Related Research News
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.
MOTS-c Guide: Mitochondrial Peptide for Canada Research
MOTS-c stands out as a 16-amino-acid peptide encoded by mitochondrial DNA, distinct from nuclear-gene peptides. Discovered in 2015, it influences metabolic regulation, AMPK signaling, and aging mechanisms. This guide details its features, verification steps, and research applications for Canadian buyers.
MOTS-c: The Mitochondrial Peptide for Metabolic Health
MOTS-c, a 16-amino-acid peptide encoded by mitochondrial DNA, regulates metabolism and responds to stress by signaling from mitochondria to the nucleus. Research shows it activates AMPK, declines with age, and mimics exercise effects in preclinical models. Studies link lower levels to type 2 diabetes and age-related physical decline.